Evidence map›Paper›PMID 33223221›Full record

ArticleGynecologic oncology2021

Perioperative SARS-CoV-2 infection among women undergoing major gynecologic cancer surgery in the COVID-19 era: A nationwide, cohort study from Turkey.

Ali Ayhan, Murat Oz, Nazli Topfedaisi Ozkan, Koray Aslan, Müfide Iclal Altintas, Hüseyin Akilli, Erdal Demirtas, Osman Celik, Mustafa Mahir Ülgü, Suayip Birinci and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Gynecologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ali AyhanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Başkent University, Ankara, Turkey.
Murat OzDepartment of Gynecologic Oncology, Ankara City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey. Electronic address: ozmurat@gmail.com.
Nazli Topfedaisi OzkanDepartment of Obstetrics and Gynecology, Ankara Education and Training Hospital, University of Health Sciences, Ankara, Turkey.
Koray AslanDepartment of Gynecologic Oncology, Ankara City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Müfide Iclal AltintasDepartment of Obstetrics and Gynecology, Ankara City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Hüseyin AkilliDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Başkent University, Ankara, Turkey.
Erdal DemirtasGeneral Directorate of Information Systems, Ministry of Health, Republic of Turkey, Ankara, Turkey.
Osman CelikGeneral Directorate of Public Hospitals, Ministry of Health, Republic of Turkey, Ankara, Turkey.
Mustafa Mahir ÜlgüGeneral Directorate of Information Systems, Ministry of Health, Republic of Turkey, Ankara, Turkey.
Suayip BirinciDeputy Minister of Health, Ministry of Health, Republic of Turkey, Ankara, Turkey.
Mehmet Mutlu MeydanliDepartment of Gynecologic Oncology, Ankara City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Sağlık Bilimleri Üniversitesi · TRMinistry of Health · TRBaşkent University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of this study was to determine the rate of perioperative SARS-CoV-2 infection among gynecologic cancer patients undergoing major surgery.

methodsThe database of the Turkish Ministry of Health was searched in order to identify all consecutive gynecologic cancer patients undergoing major surgery between March 11, 2020 and April 30, 2020 for this retrospective, nationwide, cohort study. The inclusion criteria were strictly founded on a final histopathological diagnosis of a malignant gynecologic tumor. COVID-19 cases were diagnosed by reverse transcriptase- polymerase chain reaction testing for SARS-CoV-2. The rate of perioperative SARS-CoV-2 infection and the 30-day mortality rate of COVID-19 patients were investigated.

resultsDuring the study period, 688 women with gynecologic cancer undergoing major surgery were identified nationwide. The median age of the patients was 59 years. Most of the surgeries were open (634/688, 92.2%). There were 410 (59.6%) women with endometrial cancer, 195 (28.3%) with ovarian cancer, 66 (9.6%) with cervical cancer, 14 (2.0%) with vulvar cancer and 3 (0.4%) with uterine sarcoma. The rate of SARS-CoV-2 infections confirmed within 7 days before or 30 days after surgery was 46/688 (6.7%). All but one woman was diagnosed postoperatively (45/46, 97.8%). The rates of intensive care unit admission and invasive mechanical ventilation were 4/46 (8.7%) and 2/46 (4.3%), respectively. The 30-day mortality rate was 0%.

conclusionIn the COVID-19 era, gynecologic cancer surgery may be performed with an acceptable rate of perioperative SARS-CoV-2 infection if the staff and the patients strictly adhere to the established infection control measures.

Indexed as

SARS-CoV-2AdolescentAdultAgedAged, 80 and overCOVID-19FemaleGenital Neoplasms, FemaleHumansMiddle AgedPerioperative PeriodRetrospective StudiesTurkeyYoung AdultCoronavirus infectionGynecologic neoplasmsPeriodPerioperativeSevere acute respiratory syndromeSurgery

Identifiers

PMID33223221
PMCPMC7670981
OpenAlexW3104176640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.